KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Revenue (2019 - 2025)

Historic Revenue for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $609.3 million.

  • Royalty Pharma's Revenue rose 789.83% to $609.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 370.0%. This contributed to the annual value of $2.3 billion for FY2024, which is 386.39% down from last year.
  • As of Q3 2025, Royalty Pharma's Revenue stood at $609.3 million, which was up 789.83% from $578.7 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Revenue peaked at $684.0 million during Q1 2023, and registered a low of $536.0 million during Q2 2022.
  • Moreover, its 5-year median value for Revenue was $568.2 million (2025), whereas its average is $573.7 million.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 2169.24% in 2023, then plummeted by 1695.88% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Revenue stood at $575.7 million in 2021, then dropped by 1.73% to $565.7 million in 2022, then grew by 5.36% to $596.1 million in 2023, then dropped by 0.41% to $593.6 million in 2024, then increased by 2.64% to $609.3 million in 2025.
  • Its Revenue stands at $609.3 million for Q3 2025, versus $578.7 million for Q2 2025 and $568.2 million for Q1 2025.